{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:37Z","timestamp":1789972117184,"version":"4.0.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.tripleo.2010.04.049","type":"journal-article","created":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T04:41:27Z","timestamp":1281415287000},"page":"463-469","source":"Crossref","is-referenced-by-count":84,"title":["Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases"],"prefix":"10.1016","volume":"110","author":[{"given":"Sebastian","family":"Hoefert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Eufinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tripleo.2010.04.049_bib1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2010.04.049_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1601-0825.2007.01381.x","article-title":"Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis","volume":"14","author":"Sarin","year":"2008","journal-title":"Oral Dis"},{"key":"10.1016\/j.tripleo.2010.04.049_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.joms.2009.01.009","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2010.04.049_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2010.04.049_bib5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/154405910708601101","article-title":"Osteonecrosis of the jaws and bisphosphonate therapy","volume":"86","author":"Ruggiero","year":"2007","journal-title":"J Dent Res"},{"key":"10.1016\/j.tripleo.2010.04.049_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"Yoneda","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.tripleo.2010.04.049_bib7","first-page":"417","article-title":"A review of bisphosphonate- associated osteonecrosis of the jaws and its management","volume":"73","author":"Lam","year":"2007","journal-title":"J Can Dent Assoc"},{"key":"10.1016\/j.tripleo.2010.04.049_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma","volume":"12","author":"Rock","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.tripleo.2010.04.049_bib9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1345\/aph.1K592","article-title":"Sunitinib adverse event: oral bullous and lichenoid mucositis","volume":"43","author":"Mignogna","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.tripleo.2010.04.049_bib10","first-page":"41","article-title":"Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects","volume":"1","author":"Kollmannsberger","year":"2007","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.tripleo.2010.04.049_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00520-008-0409-1","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.tripleo.2010.04.049_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?","volume":"45","author":"Lesclous","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.tripleo.2010.04.049_bib13","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tripleo.2010.04.049_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.tripleo.2010.04.049_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/archderm.144.1.123","article-title":"Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis","volume":"144","author":"Suwattee","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.tripleo.2010.04.049_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1359\/jbmr.090713","article-title":"Cancer treatment dosing regimens of zoledronic acid result in near complete suppression of mandible intra-cortical bone remodeling in beagle dogs","volume":"25","author":"Allen","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tripleo.2010.04.049_bib17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.joms.2008.01.038","article-title":"Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment","volume":"66","author":"Allen","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2010.04.049_bib18","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210410003021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210410003021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T18:26:44Z","timestamp":1544293604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079210410003021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S1079210410003021"],"URL":"https:\/\/doi.org\/10.1016\/j.tripleo.2010.04.049","relation":{},"ISSN":["1079-2104"],"issn-type":[{"value":"1079-2104","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}